Identification of Wild-Derived Inbred Mouse Strains Highly Susceptible to Monkeypox Virus Infection for Use as Small Animal Models
-
Published:2010-08-15
Issue:16
Volume:84
Page:8172-8180
-
ISSN:0022-538X
-
Container-title:Journal of Virology
-
language:en
-
Short-container-title:J Virol
Author:
Americo Jeffrey L.1, Moss Bernard1, Earl Patricia L.1
Affiliation:
1. Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
Abstract
ABSTRACT
Infection with monkeypox virus (MPXV) causes disease manifestations in humans that are similar, although usually less severe, than those of smallpox. Since routine vaccination for smallpox ceased more than 30 years ago, there is concern that MPXV could be used for bioterrorism. Thus, there is a need to develop animal models to study MPXV infection. Accordingly, we screened 38 inbred mouse strains for susceptibility to MPXV. Three highly susceptible wild-derived inbred strains were identified, of which CAST/EiJ was further developed as a model. Using an intranasal route of infection with an isolate of the Congo Basin clade of MPXV, CAST/EiJ mice exhibited weight loss, morbidity, and death in a dose-dependent manner with a calculated 50% lethal dose (LD
50
) of 680 PFU, whereas there were no deaths of BALB/c mice at a 10,000-fold higher dose. CAST/EiJ mice exhibited greater MPXV sensitivity when infected via the intraperitoneal route, with an LD
50
of 14 PFU. Both routes resulted in MPXV replication in the lung, spleen, and liver. Intranasal infection with an isolate of the less-pathogenic West African clade yielded an LD
50
of 7,600 PFU. The immune competence of CAST/EiJ mice was established by immunization with vaccinia virus, which induced antigen-specific T- and B-lymphocyte responses and fully protected mice from lethal doses of MPXV. The new mouse model has the following advantages for studying pathogenesis of MPXV, as well as for evaluation of potential vaccines and therapeutics: relative sensitivity to MPXV through multiple routes, genetic homogeneity, available immunological reagents, and commercial production.
Publisher
American Society for Microbiology
Subject
Virology,Insect Science,Immunology,Microbiology
Reference33 articles.
1. Breman, J. G., R. Kalisa, M. V. Steniowski, E. Zanotto, A. I. Gromyko, and I. Arita. 1980. Human monkeypox, 1970-79. Bull. World Health Organ.58:165-182. 2. Chen, N., G. Li, M. K. Liszewski, J. P. Atkinson, P. B. Jahrling, Z. Feng, J. Schriewer, C. Buck, C. Wang, E. J. Lefkowitz, J. J. Esposito, T. Harms, I. K. Damon, R. L. Roper, C. Upton, and R. M. Buller. 2005. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology340:46-63. 3. Davis, R. C., A. Jin, M. Rosales, S. Yu, X. Xia, K. Ranola, E. E. Schadt, and A. J. Lusis. 2007. A genome-wide set of congenic mouse strains derived from CAST/Ei on a C57BL/6 background. Genomics90:306-313. 4. Earl, P. L., J. L. Americo, L. S. Wyatt, L. A. Eller, D. C. Montefiori, R. Byrum, M. Piatak, J. D. Lifson, R. R. Amara, H. L. Robinson, J. W. Huggins, and B. Moss. 2007. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology366:84-97. 5. Earl, P. L., J. L. Americo, L. S. Wyatt, O. Espenshade, J. Bassler, K. Gong, S. Lin, E. Peters, L. Rhodes, Jr., Y. E. Spano, P. M. Silvera, and B. Moss. 2008. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl. Acad. Sci. U. S. A.105:10889-10894.
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Animal models of mpox virus infection and disease;Infectious Medicine;2023-09 2. Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice;Antiviral Research;2023-08 3. Human monkeypox: history, presentations, transmission, epidemiology, diagnosis, treatment, and prevention;Frontiers in Medicine;2023-07-20 4. Human Monkeypox: A Comprehensive Overview of Epidemiology, Pathogenesis, Diagnosis, Treatment, and Prevention Strategies;Pathogens;2023-07-18 5. Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge;Frontiers in Immunology;2023-06-26
|
|